Research suite
Formulation, optimization, FTO, patent drafting, VCM process design, and analytics, each agent anchored to IID precedent, Drugs@FDA, EMA EPAR, and the global pharma patent corpus. Outputs every formulation chemist actually uses: candidate cards, delta memos, FTO maps, USPTO-formatted drafts.
Fig 01 · Research workflow
Research informs Formulation. FTO clears chemistry before scale-up. Optimization refines the candidate. VCM sets the manufacturing window. Patent Drafting captures the work. Analytics ranks the features that move outcomes and turns those rankings into design constraints for the next cycle.
The threading bar walks the full candidate-development flow in order, from Research through to Analytics as the seventh and final step.
Per agent
Click any agent in the choreography above to jump to its deep section.
Designs the formulation. Cites the IID precedent.
“Design an oral formulation for this poorly soluble compound.”
Example prompt
Reads the indication, the API physicochemistry, and the program target product profile. Proposes formulations grounded in IID excipient ceilings, GRAS conclusions, and the precedent dosage forms in Drugs@FDA. Operates per ICH Q8(R2). When the API physicochemistry suggests a specialized form (BCS Class II → ASD, BCS Class IV → cyclodextrin or lipid carrier, sensitive biologic → lyophilized cake), the agent dispatches to VCM Process Design or Optimization to refine the manufacturing window before returning the final candidate.
Returns: 3-5 candidate cards (F01-F0N) with rationale, IID precedent, and a one-line risk note on each.
| Excipient | Function | % w/w |
|---|---|---|
| Active | API | 35 |
| HPMC K100M | Hydrophilic matrix former | 30 |
| Lactose monohydrate | Filler | 25 |
| Microcrystalline cellulose | Filler / binder | 8.5 |
| Magnesium stearate | Lubricant | 1 |
| Colloidal silicon dioxide | Glidant | 0.5 |
HPMC K100M selected as the primary release-control matrix at 30% w/w; concentration sits within IID precedent for oral MR products on Mirapex ER (NDA 022030). Lactose monohydrate and MCC chosen for direct-compression compatibility and to stabilise the API in a low-water-activity matrix.
Fig. Candidate card returned by the Formulation Agent (illustrative).
Refines a working candidate against a single objective.
“Optimize this tablet for 20% cost reduction while maintaining dissolution.”
Example prompt
Takes a working candidate and pushes it against a single objective: cost, manufacturability, dissolution, or stability. Substitutes excipients within IID-precedented ranges. Cross-references substitutions against the FDA Drug Master File listings (40k+) to confirm a qualified supplier exists at scale. Flags every substitution that would void a regulatory precedent.
Returns: A revised candidate card plus a delta memo against the original.
Synthesizes the literature with primary-source citations.
“Compare lipid-based vs amorphous solid dispersion approaches for BCS Class II compounds.”
Example prompt
Compares formulation strategies across PubMed (37M records), ClinicalTrials.gov + AACT, EMA EPAR, and Drugs@FDA reviews. Cites primary sources with DOI, PMID, or application number. Flags conflicting evidence. Returns a single coherent comparative memo rather than a paragraph of prose with citations sprinkled in.
Returns: A comparative memo with a tier-anchored citation list.
Scores patent risk before chemistry. Treats claims as design constraints.
“Analyze FTO for an HPMC-based extended-release tablet for Drug X.”
Example prompt
Risk-scores each candidate scaffold (0-100) against the global pharma patent corpus, identifies blocking claims line by line, and proposes design-arounds. For ANDA programs, the agent reads the Orange Book, distinguishes Drug Substance / Drug Product / Use Patents, and recommends a Paragraph III versus Paragraph IV filing strategy.
Returns: An FTO map with claim-by-claim blocking analysis and three non-infringing alternatives.
Drafts USPTO-formatted patent applications.
“Draft a USPTO nonprovisional for F02 with three independent claims.”
Example prompt
Writes the specification, dependent claims, and prior-art distinction memo against MPEP §608 and 37 CFR §1.84. Pulls embodiments from the candidate cards already produced earlier in the conversation. Drafts (PA01, PA02…) stream live into the side panel as the agent writes. The agent does not fabricate experimental data: it uses explicit [PLACEHOLDER - TO BE DETERMINED], [REQUIRES ICH STABILITY STUDY], and [REQUIRES DISSOLUTION STUDY] markers for stability, dissolution, comparative-study, and bioequivalence data, since those have to come from your laboratory work.
Returns: A USPTO-formatted draft application; your patent counsel signs.
Recommends manufacturing parameters for VCM, HME, spray drying.
“Design a VCM screen for ITZ on Kollidon VA 64 vs HPMCAS-L.”
Example prompt
Specialized for MeltPrep Vacuum Compression Molding, with HME pre-screening built in. Sets process windows for VCM, hot-melt extrusion, and spray drying. VCM screens drug-polymer pairs in minutes per formulation, versus 30-60 minutes for HME, with near-zero material loss. Working knowledge of common ASD polymers (Parteck MXP, Kollidon VA 64, Soluplus, Eudragit EPO, HPMCAS-L/M/H, Klucel, Methocel).
Returns: A VCM process card with operating ranges and the boundary studies needed to qualify them.
Builds the model from your data. Feeds insights back to other agents.
“Run a DoE-matrix analysis on this dissolution dataset and report optimal parameter ranges.”
Example prompt
Trains predictive models on uploaded experimental datasets (Random Forest, gradient boosting, logistic regression). Ranks the features that move the outcome and feeds those features back to the Formulation and Optimization agents as new design constraints. The sandbox runs server-side, so results stream identically to web, desktop, and mobile.
Returns: A research-grade PDF report with methodology, results, and feature-importance rankings; updated constraints applied to the conversation context.
Biologics suite
Biologics Research, FTO, and Formulation & CMC, anchored to ICH Q5A-E, Q6B, Q13, Q14, FDA Purple Book, EMA biosimilar register, SAbDab, and PLAbDab.
Safety suite
ERA, extractables, leachables, nitrosamines, OEL, and PDE, anchored to ICH M7, EMA HBEL, USP <1664>, and ECETOC TR 101.
Architecture
Reality Anchor, agent routing, foundation, regulatory frameworks, and data sources: the unified platform overview.
Tell us what you are working on (molecule, indication, stage, open question).
A formulation lead will be in touch within a business day.